49.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$49.89
Aprire:
$49.81
Volume 24 ore:
1.37M
Relative Volume:
0.61
Capitalizzazione di mercato:
$8.06B
Reddito:
$1.17B
Utile/perdita netta:
$150.71M
Rapporto P/E:
52.45
EPS:
0.94
Flusso di cassa netto:
$245.03M
1 W Prestazione:
-4.51%
1M Prestazione:
+5.39%
6M Prestazione:
-32.22%
1 anno Prestazione:
-33.07%
Bio Techne Corp Stock (TECH) Company Profile
Nome
Bio Techne Corp
Settore
Industria
Telefono
(612) 379-8854
Indirizzo
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Confronta TECH con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
TECH
Bio Techne Corp
|
49.30 | 8.06B | 1.17B | 150.71M | 245.03M | 0.94 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.54 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
511.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
313.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
540.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
257.51 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-30 | Iniziato | Wells Fargo | Overweight |
2025-04-09 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
2025-03-18 | Iniziato | Evercore ISI | Outperform |
2025-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
2024-02-08 | Iniziato | Scotiabank | Sector Outperform |
2024-02-02 | Downgrade | Stifel | Buy → Hold |
2023-12-07 | Iniziato | UBS | Buy |
2023-08-28 | Iniziato | William Blair | Outperform |
2023-01-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
2022-12-14 | Iniziato | Deutsche Bank | Buy |
2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
2022-08-25 | Iniziato | Credit Suisse | Outperform |
2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
2021-09-15 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-03-08 | Aggiornamento | Stephens | Equal-Weight → Overweight |
2021-02-23 | Aggiornamento | Stifel | Hold → Buy |
2021-01-25 | Reiterato | The Benchmark Company | Buy |
2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
2020-09-30 | Iniziato | Atlantic Equities | Overweight |
2020-07-15 | Downgrade | Stephens | Overweight → Equal-Weight |
2020-05-27 | Downgrade | Stifel | Buy → Hold |
2020-05-14 | Iniziato | The Benchmark Company | Buy |
2020-01-08 | Ripresa | Stephens | Overweight |
2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
2020-01-07 | Iniziato | Citigroup | Neutral |
2019-11-15 | Iniziato | Stifel | Buy |
2019-07-02 | Aggiornamento | Janney | Neutral → Buy |
2019-01-14 | Aggiornamento | Stephens | Equal-Weight → Overweight |
2018-10-31 | Downgrade | Craig Hallum | Buy → Hold |
2018-10-17 | Iniziato | Goldman | Neutral |
2018-06-15 | Iniziato | Argus | Buy |
2017-07-13 | Iniziato | Wells Fargo | Market Perform |
2017-02-09 | Iniziato | Citigroup | Buy |
2017-01-18 | Iniziato | Deutsche Bank | Buy |
2016-11-10 | Ripresa | Leerink Partners | Outperform |
2015-01-21 | Reiterato | Robert W. Baird | Outperform |
2013-09-20 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
Mostra tutto
Bio Techne Corp Borsa (TECH) Ultime notizie
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
How the (TECH) price action is used to our Advantage - news.stocktradersdaily.com
Bio-Techne Director Cashes Out in Significant Stock Sale - TipRanks
Bio-Techne at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com
TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts - Yahoo Finance
Transcript : Bio-Techne Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener
Bio-Techne To Present At Goldman Sachs Global Healthcare Conference; Webcast At 10:40 AM ET - Nasdaq
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics - Yahoo Finance
Bio-Techne (TECH) Maintains 'Buy' Rating with $75 Price Target | TECH Stock News - GuruFocus
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact By Investing.com - Investing.com South Africa
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact - Investing.com India
Stochastic Optical Reconstruction Miicroscope Market Size, - openPR.com
Deutsche Bank Adjusts Bio-Techne Price Target to $66 From $70 - marketscreener.com
Bio-Techne at Jefferies Conference: Strategic Growth Amid Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03 - marketscreener.com
Bio-Techne at William Blair Growth Stock: Strategic Insights and Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 02 - marketscreener.com
Spotting Winners: Bio-Techne (NASDAQ:TECH) And Research Tools & Consumables Stocks In Q1 - Yahoo Finance
Wells Fargo Begins Coverage of Bio-Techne (TECH) Stock, Gives PT of $59 - Insider Monkey
Wells Fargo starts Bio-Techne with Overweight, $59 target - Investing.com Australia
Bio-Techne stock price target cut to $65 by Argus - Investing.com South Africa
Wells Fargo Initiates Coverage on Bio-Techne (TECH) with Overwei - GuruFocus
Wells Fargo starts Bio-Techne with Overweight, $59 target By Investing.com - Investing.com Canada
Demystifying Bio-Techne: Insights From 7 Analyst Reviews - Benzinga
Argus Adjusts Price Target on Bio-Techne to $65 From $90 - marketscreener.com
Wells Fargo Initiates Bio-Techne at Overweight With $59 Price Target - marketscreener.com
Bio-Techne Corporation (TECH): A Bull Case Theory - Insider Monkey
Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment! - Smartkarma
Is Bio-Techne Stock The Right Pick For Your Portfolio Now? - Barchart.com
Is Bio-Techne Stock the Right Pick for Your Portfolio Now? - Yahoo Finance
Bio-Techne Sets Triple Conference Appearance: William Blair, Jefferies, and Goldman Sachs in June - Stock Titan
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
Cetera Investment Advisers Sells 887 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Exosomes Market Projected to Reach USD 1,311.03 Million by - GlobeNewswire
Do Wall Street Analysts Like Bio-Techne Stock? - MSN
(TECH) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bio-Techne (NASDAQ:TECH) Rating Increased to Buy at StockNews.com - Defense World
Ex-Dividend Reminder: Bio-Techne, First Hawaiian and Affiliated Managers Group - Nasdaq
Wednesday Sector Laggards: Healthcare, Materials - Nasdaq
What Makes Bio-Techne Corporation (TECH) a Compelling Addition? - Insider Monkey
ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) - Quantisnow
Bio Techne Corp Azioni (TECH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bio Techne Corp Azioni (TECH) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Herr Amy E. | Director |
Jun 09 '25 |
Sale |
49.77 |
1,280 |
63,705 |
1,976 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):